表紙
市場調查報告書

搭配診斷:生物標記平台的精密醫療

Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine

出版商 Frost & Sullivan 商品編碼 746078
出版日期 內容資訊 英文 59 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
搭配診斷:生物標記平台的精密醫療 Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine
出版日期: 2018年11月13日內容資訊: 英文 59 Pages
簡介

預測和預後生物標誌物構成了每個癌症標靶藥物發現和開發計劃的核心要素。利用生物標誌物進行腫瘤學的突破性技術為個性化醫療和精確腫瘤學拓展了道路。

本報告提供全球搭配診斷市場相關調查,彙整市場趨勢與技術趨勢,製藥產業帶來的影響,商務策略模式,基準相關資訊。

第1章 摘要整理

第2章 技術概要與趨勢

  • 分析的重要要素
  • 搭配診斷概要
  • 搭配診斷的有效性和性能驗證
  • 癌症搭配診斷的全貌
  • 精密腫瘤學加速途徑
  • 用於搭配診斷的生物標記層
  • 搭配診斷的新興機會

第3章 技術趨勢檢討與評估

  • 技術協同效應重塑價值鏈
  • 產品開發與商品化
  • 技術與商務趨勢:加速因素
  • 技術與商務趨勢:課題
  • 促進搭配診斷解決方案的新方法

第4章 搭配診斷對製藥產業的影響

  • 市場趨勢與機會
  • 技術焦點
  • 治療領域和各地區市場區隔
  • 搭配診斷對治療領域的影響
  • 傑出的醫藥市場領導者

第5章 商務策略模式

  • 利益相關者在企業戰略中的作用
  • 技術轉移評估與認識
  • 破壞性解決方案
  • 經營模式混合化
  • 整體環境影響因素
  • 未來發展預測

第6章 資金籌措與投資

  • 主要的機會
  • 資金籌措·投資模式與引進
  • 長期的預測,證券化,信用
  • 策略性聯合

第7章 實際成果基準

  • 多標準基準測試方法
  • 策略性組合評估
  • 技術創新
  • 財務實際成果
  • 市場部署
  • 成功的關鍵行動
  • 分析實際成果結果
  • 多標準最後評估
  • 策略性因素:重要的成功因素

第8章 主要產業影響因素

目錄
Product Code: D83E

Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy

Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs. Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Companion Diagnostics: The Bigger Picture
  • 1.2. Research Focus: Advancing New Diagnostics and Therapeutics
  • 1.3. Research Scope: Unveiling Novel Diagnostics Pathways
  • 1.4. Analysis Framework: Frost & Sullivan's Core Value
  • 1.5. Research Methodology: Five Steps toward Success

2.0. TECHNOLOGY SNAPSHOT AND TRENDS

  • 2.1. Key Elements of Analysis: The ‘Companion Diagnostics' Concept
  • 2.2. Brief Overview of Companion Diagnostics
  • 2.3. Effectiveness and Performance Validation for CDx
  • 2.4. Overall Landscape of Cancer Companion Diagnostics
  • 2.5. Precision Oncology Accelerated Pathway
  • 2.6. Biomarker Stratification for Companion Diagnostics
  • 2.7. Emerging Opportunities for Companion Diagnostics

3.0. TECHNOLOGY STATUS REVIEW AND ASSESSMENT

  • 3.1. Technology Synergy Reshaping Value Chain
  • 3.2. Product Development and Commercialization
  • 3.3. Technology and Business Landscape: Accelerators
  • 3.4. Technology and Business Landscape: Challenges
  • 3.5. New Approaches Driving Companion Diagnostics Solutions

4.0. IMPACT OF COMPANION DIAGNOSTICS ON THE PHARMACEUTICAL INDUSTRY

  • 4.1. Market Dynamics and Opportunities
  • 4.2. Market Potential: Technology Focus Segmentation
  • 4.3. Market Potential: Therapeutic Area and Regional Segmentation
  • 4.4. Impact of Companion Diagnostics on Therapeutic Areas
  • 4.5. Prominent Pharmaceutical Market Leaders

5.0. BUSINESS STRATEGY MODELS

  • 5.1. The Role of Stakeholders in Business Strategy
  • 5.2. Technology Transfer Assessment and Perceptions
  • 5.3. Disruptive Companion Diagnostics Solutions
  • 5.4. Business Model Hybridization
  • 5.5. Overall Environmental Impact Factors
  • 5.6. Future Perspective for Companion Diagnostics

6.0. FUNDING AND INVESTMENT LANDSCAPE

  • 6.1. Key Funding and Investment Opportunities
  • 6.2. Funding and Investment Models and Adoption
  • 6.3. Funding Long Shots, Securitization, and Credit
  • 6.4. Strategic Collaborations

7.0. PERFORMANCE BENCHMARKING

  • 7.1. Multicriteria Approach for Benchmarking
  • 7.2. Strategic Portfolio Assessment
  • 7.3. Level 1 Criteria: Innovation Development
  • 7.4. Level 1 Criteria: Financial Performance
  • 7.5. Level 1 Criteria: Market Evolution
  • 7.6. Level 2 Criteria: Key Actions for Success
  • 7.7. Analytic Performance Results
  • 7.8. Multicriteria Final Assessment
  • 7.9. Strategic Imperatives: Critical Success Factors

8.0. KEY INDUSTRY INFLUENCERS

  • 8.1. Key Industry Influencers
  • 8.1. Key Industry Influencers (continued)
  • 8.1. Key Industry Influencers (continued)
  • 8.1. Key Industry Influencers (continued)
  • 8.1. Key Industry Influencers (continued)
  • Legal Disclaimer
Back to Top